Future topics for IMI call 17 published

Future topics for IMI call 17 published

New future topics draft texts for IMI call 17 have been published. Although these topics are not final yet, it is at this stage unlikely that they will change. We have summarised the most important information below.

Optimising future obesity treatment

The aim of this topic is to identify pathophysiologically and clinically meaningful subgroups of obesity that will allow for optimisation of prevention and treatment for obesity and complications. Leading to an optimised and more personalised future obesity treatment, the identified patient subgroups should be analysed for treatment results, including weight loss and weight maintenance, and prevention and/or development of complications.

Open access chemogenomics library and chemical probes for the druggable genome

The aim is to generate potent, well-characterized functional small molecule modulators for a significant number of the druggable genome and, at the same time, lay the foundation for identifying a set of openly accessible (i.e. unencumbered from restriction on use) tool compounds for the entire druggable human genome. With this set of chemical tools available, scientists will be poised to interrogate the latest findings emerging from big data approaches and human genetic studies, thus compressing time from gene discovery to target prioritisation, and ultimately to patient benefits. It is imperative to fill the significant gaps by discovering and developing novel chemical tools/probes against under-studied proteins (or protein families) that may be involved in the initiation and progression of disease.

Intelligent prediction and identification of environmental risks posed by human medicinal products

The aim is to ensure the environmental safety of human medicinal products through patient use by providing innovative and predictive tools to:

  • identify environmental hazards and risks associated with candidates in drug development;
  • screen and prioritise established, ‘legacy’ pharmaceuticals for a tailored environmental assessment;
  • make environmental data for human medicinal products more transparent to all stakeholders through the development of a publicly available database.

For more information and the full call texts visit the website of IMI.

Subscribe

Subscribe to our newsletter to receive news and resources about funding for life sciences and innovations.


Photo by rawpixel on Unsplash

All services

In our approach we combine both non-dilutive and dilutive funding. Let’s start working on your project together now!

 

Welcome at Catalyze!

Catalyze uses cookies in order to improve your user experience. By using this website you agree to our policy.

Go back or